

***Fiscal Year 2023 Department of Defense Kidney Cancer Research Program (KCRP)
Reference Table of Award Mechanisms and Submission Requirements***

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|---|--|---|---|
| <p>Academy of Kidney Cancer Scholars – Early-Career Scholar Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-KCRP-AKCIECSA</p> | <p>Investigators within 4 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline. <i>A letter attesting to eligibility required.</i></p> | <ul style="list-style-type: none"> • Supports addition of new Early-Career Scholars (ECS) to the unique, interactive virtual academy, which provides intensive mentoring, national networking, and a peer group for junior faculty. • ECS whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply. • Requires Designated Mentor who is an independent, established kidney cancer investigator with a record of kidney cancer publications in peer-reviewed journals. • Designated Mentor not required to be at the same institution as the ECS. • <i>Preliminary data are required.</i> • <i>Funding for clinical trials is not allowed.</i> • <i>Submission of a Letter of Intent is required prior to full application submission.</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$725,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. | <p>Pre-Application (Preproposal): September 15, 2023 5:00 p.m. Eastern time</p> <p>Application: October 6, 2023 11:59 p.m. Eastern time</p> |
| <p>Clinical Consortium Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-KCRP-CCA</p> | <p>The Coordinating Center and each Clinical Research Site Principal Investigator must be an independent investigator with a faculty-level appointment (or equivalent).</p> | <ul style="list-style-type: none"> • Supports a consortium to facilitate the rapid execution of collaborative phase 1 and 2 clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease the impact of kidney cancer. • Provides support for a network of organizations that will include one coordinating center and multiple clinical research sites. • All sites selected and will be jointly responsible for proposing, selecting, and conducting trials. • Coordinating center and clinical research sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer and/or military populations. • Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction, or aggressiveness, and/or progression of kidney cancer are encouraged. | <p>Coordinating Center</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$6,000,000 for direct costs. <p>Clinical Research Sites</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$800,000 for direct costs. • The maximum period of performance for the Coordinating Center and Clinical Research Sites is 4 years. | <p>Pre-Application (Preproposal): October 26, 2023 5:00 p.m. Eastern time</p> <p>Application: November 9, 2023 11:59 p.m. Eastern time</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|--|--|---|
| <p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-KCRP-CTA</p> | <p>Independent investigators at all levels.</p> | <ul style="list-style-type: none"> • Supports hypothesis-based, early-phase clinical trials (e.g., phase 0, phase 1, pilot phase 2) to test interventions that will have a major impact in the field of kidney cancer. • Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other types. • Investigational New Drug or Investigational Device Exemption application approvals, if applicable, must be in place by the time of application submission. • Letter of support demonstrating proof of possession of sufficient drug supply to conduct study must be provided (if appropriate). • <i>Clinical trials are expected to be initiated within 12 months of the award date.</i> • <i>Submission of a Letter of Intent required prior to full application submission.</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,500,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. | <p>Pre-Application (Preproposal): September 15, 2023 5:00 p.m. Eastern time</p> <p>Application: October 6, 2023 11:59 p.m. Eastern time</p> |
| <p>Concept Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-KCRP-CA</p> | <p>Independent investigators at all levels.</p> | <ul style="list-style-type: none"> • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer. • Emphasis on innovation. • Funding for clinical trials is not allowed. • Preliminary data are not allowed and should not be submitted. • Blinded review. • <i>Submission of a Letter of Intent is required prior to full application submission.</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$100,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 1 years. | <p>Pre-Application (Preproposal): July 20, 2023 5:00 p.m. Eastern time</p> <p>Application: August 3, 2023 11:59 p.m. Eastern time</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|--|---|---|---|
| <p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-KCRP-IDA</p> | <p>Investigators at or above the level of Assistant Professor (or equivalent).</p> | <ul style="list-style-type: none"> • Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research and have the potential to make an important contribution to kidney cancer. • Preliminary data are required. • Innovation and impact are the most important review criteria. • Funding for clinical trials is not allowed. <p>New FY23 Partnering Principal Investigator Option:</p> <ul style="list-style-type: none"> • Supports two investigators, termed Initiating and Partnering Principal Investigator, to partner on a single application. • Each PI is expected to bring distinct contributions to the application. • The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. • Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most or all of the experiments and analyses do not meet the intent of the Partnering PI Option. • Submission of a Letter of Intent is required prior to full application submission. | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$800,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. <p>Partnering PI Option:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,200,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. | <p>Pre-Application (Preproposal): September 15, 2023 5:00 p.m. Eastern time</p> <p>Application: October 6, 2023 11:59 p.m. Eastern time</p> |
| <p>Nurse-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-KCRP-NIRA</p> | <p>As of full application submission deadline, investigators:</p> <ul style="list-style-type: none"> • Must be licensed registered nurse and/or • Have a terminal degree of DNP or PhD in Nursing (or equivalent). | <ul style="list-style-type: none"> • Supports innovative, high-impact kidney cancer research, conducted by nurses working in clinical practice and/or an academic environment (DNP or PhD), to advance ideas or clinical care. • Demonstrate potential to have a major impact in kidney cancer, ideally in a multi-disciplinary manner led by a nurse. • Submission of a Letter of Intent required prior to full application submission. | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$300,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. | <p>Pre-Application (Preproposal): September 15, 2023 5:00 p.m. Eastern time</p> <p>Application: October 6, 2023 11:59 p.m. Eastern time</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|--|---|--|---|
| <p>Postdoctoral and Clinical Fellowship Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-KCRP-PCFA</p> | <p>As of full application submission deadline, investigators:</p> <ul style="list-style-type: none"> • Must possess a doctoral and/or medical degree (or equivalent). • Have 4 years or less of postdoctoral and/or mentored clinical research training experience (excluding family medical leave). <p>All other academic ranks are ineligible.</p> | <ul style="list-style-type: none"> • Supports research opportunities focused on kidney cancer for individuals in the early stages of their careers. • Requires participation of a Designated Mentor who is an experienced kidney cancer researcher. • <i>Submission of a Letter of Intent is required prior to full application submission.</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$195,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. | <p>Pre-Application (Preproposal): July 20, 2023 5:00 p.m. Eastern time</p> <p>Application: August 3, 2023 11:59 p.m. Eastern time</p> |
| <p>Translational Research Partnership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-KCRP-TRPA</p> | <p>Investigators at or above the level of Assistant Professor (or equivalent).</p> <p>One partner must have experience in kidney cancer or kidney cancer patient care.</p> | <ul style="list-style-type: none"> • Supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications. • This award supports the development of translational research collaborations between two independent, faculty-level investigators to address a central problem or question in kidney cancer in a manner that would be less readily achievable through separate efforts. • Supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research relevant to kidney cancer. • Supports translational correlative studies. • Preliminary data to support the feasibility of the research hypothesis(es) and research approaches are required; however, these data do not necessarily need to be derived from studies of kidney cancer. • <i>Funding for clinical trials is not allowed.</i> • <i>Letter of Intent is required. An invitation to submit a full application is not required.</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$750,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. | <p>Pre-Application (Preproposal): September 15, 2023 5:00 p.m. Eastern time</p> <p>Application: October 6, 2023 11:59 p.m. Eastern time</p> |